

RECEIVED
CENTRAL FAX CENTER


JUN 29 2007

CLAIM AMENDMENTS

Please replace all prior versions and listing of claims with the amended claims as follows:

1-74. (Canceled)


75. (Withdrawn-currently amended) A method of treating or preventing an SHP-2-mediated disease or condition in a patient selected from an autoimmune disease, a proliferative disease, or an angiogenic disorder comprising the step of administering to said patient a compound selected from: ~~of formula (I-A):~~




~~or a pharmaceutically acceptable salt thereof, wherein:~~

~~Q is an optionally substituted group selected from C₁₋₃ aliphatic, C₆₋₁₀ aryl, heteroaryl having 5-10 ring atoms, and heterocyclyl having 7-10 ring atoms; and~~


~~X is selected from CH₂, C(O), or CF₂.~~




I-1





I-3



I-5



I-6



76-79. (Canceled)

80. (Withdrawn-currently amended) The method according to claim [[79]] 75 wherein said method is used to treat or prevent an autoimmune disease selected from glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves disease, autoimmune gastritis, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis, or graft vs. host disease.


81. (Withdrawn-currently amended) The method according to claim [[79]] 75 wherein said method is used to treat or prevent a proliferative disease selected from acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HTLV-1-mediated tumorigenesis.

82. (Withdrawn-currently amended) The method according to claim [[79]] 75 wherein said method is used to treat or prevent an angiogenic disorder selected from solid tumors, ocular neovascularization, and infantile haemangiomas.

83. (Withdrawn-currently amended) The method according to claim [[79]] 75 further comprising the step of administering to said patient an additional therapeutic agent.

84. (Withdrawn-currently amended) The method according to claim [[79]] 83 wherein said additional therapeutic agent is selected from a chemotherapeutic agent, an anti-proliferative agent, or an anti-inflammatory agent.


85. (Withdrawn-currently amended) A method of inhibiting SHP-2-mediated activity in a biological sample comprising the step of contacting said biological sample with a compound selected from: of formula (I-A):




or a pharmaceutically acceptable salt thereof, wherein:

~~Q is an optionally substituted group selected from C₁₋₈ aliphatic, C₆₋₁₀ aryl, heteroaryl having 5-10 ring atoms, and heterocyclyl having 3-10 ring atoms; and~~


~~X is selected from —CH₂—, —C(O)—, or —CF₃—~~




I-1




I-3




I-5




I-6




I-7




I-8




I-9




I-10



I-12




I-13




I-14

86. (Canceled)


87. (New) A compound selected from:




I-1




I-3




I-5




I-6




I-7




I-8




I-9




I-10



I-12



I-13



I-14

88. (New) A pharmaceutical composition comprising a compound according to claim 87 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

89. (New) The composition according to claim 88 wherein the composition comprises an additional therapeutic agent.